Beta-agonist Efficacy and Tolerability as Adjuvant Therapy in Myasthenia Gravis (BETA-MG)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03914638 |
|
Recruitment Status :
Recruiting
First Posted : April 15, 2019
Last Update Posted : April 17, 2019
|
Sponsor:
University of Aarhus
Information provided by (Responsible Party):
Jan Lykke Scheel Thomsen, University of Aarhus
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This study examines the effect of adjuvant therapy with the oral beta-agonist Salbutamol in patients with generalized myasthenia gravis on stable standard of care having residual symptoms.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Myasthenia Gravis | Drug: Salbutamol 4Mg Tablet Drug: Placebo oral capsule | Phase 2 Phase 3 |
Myasthenia Gravis (MG) causes various degrees of increased muscular fatigue and ocular, bulbar, respiratory and extremity symptoms.
Residual symptoms often remain despite treatment with acetylcholinesterase inhibitors and immunosuppressive agents. Escalation of immunosuppressive treatment may provide additional benefit but is associated with potentially severe side effects, and high economic costs.
Treatment with beta-agonists has been investigated in animal models of MG, and in small, randomized pilot studies of generalized MG. Adjuvant therapy with oral beta-agonists in MG may be safe and cheap and may improve symptoms.
The trial will examine the tolerability and efficacy of adjuvant therapy with the oral beta-agonist Salbutamol in patients with generalized myasthenia gravis on stable standard of care having residual symptoms.
Present study is an investigator-initiated, randomized, placebo-controlled, rater and subject-blinded crossover study.
Study consists of Screening Period (4 weeks), Treatment Period 1 (8 weeks), Washout Period (4 weeks), Treatment Period 2 (8 weeks).
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 50 participants |
| Allocation: | Randomized |
| Intervention Model: | Crossover Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | Beta-agonist Efficacy and Tolerability as Adjuvant Therapy in Myasthenia Gravis |
| Estimated Study Start Date : | April 2019 |
| Estimated Primary Completion Date : | April 2020 |
| Estimated Study Completion Date : | April 2020 |
Resource links provided by the National Library of Medicine
Genetics Home Reference related topics:
Myasthenia gravis
MedlinePlus related topics:
Myasthenia Gravis
Drug Information available for:
Albuterol
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Active
Active intervention arm. Treatment for 8 weeks per treatment period.
|
Drug: Salbutamol 4Mg Tablet
Salbutamol 4 mg, three times daily |
|
Placebo Comparator: Placebo
Placebo arm. Treatment for 8 weeks per treatment period.
|
Drug: Placebo oral capsule
Placebo, three times daily |
Primary Outcome Measures :
- Myasthenia Gravis Quality of Life 15-items (MG-QOL15) [ Time Frame: 8 weeks (Treatment Period 1), 8 weeks (Treatment Period 2) ]Validated patient reported outcome-questionnaire consisting of 15 items and their impact on quality of life. Results are reported as change from baseline to 8 weeks of treatment in both treatment periods (Visit 4 compared to Visit 2, and Visit 7 compared to Visit 5).
- Treatment Tolerability [ Time Frame: 8 weeks (Treatment Period 1), 8 weeks (Treatment Period 2) ]Tolerability assessed by rate of adverse events and drug discontinuation in both treatment periods.
Secondary Outcome Measures :
- Myasthenia Gravis Activity of Daily Living (MG-ADL) [ Time Frame: 8 weeks (Treatment Period 1), 8 weeks (Treatment Period 2) ]Validated patient-reported outcome scale consisting of 8 disease-related items and their impact on activity of daily living. Results are reported as change from baseline to 8 weeks of treatment in both treatment periods (Visit 4 compared to Visit 2, and Visit 7 compared to Visit 5).
- Neuro QOL [ Time Frame: 8 weeks (Treatment Period 1), 8 weeks (Treatment Period 2) ]Patient reported fatigue-questionnaire used to rate fatigue and impact on quality of life. Results are reported as change from baseline to 8 weeks of treatment in both treatment periods (Visit 4 compared to Visit 2, and Visit 7 compared to Visit 5).
- Quantitative Myasthenia Gravis (QMG) [ Time Frame: 8 weeks (Treatment Period 1), 8 weeks (Treatment Period 2) ]Validated rating scale consisting of 13 items measuring muscle function and endurance. Results are reported as change from baseline to 8 weeks of treatment in both treatment periods (Visit 4 compared to Visit 2, and Visit 7 compared to Visit 5).
- Myasthenia Gravis Composite (MG-Composite) [ Time Frame: 8 weeks (Treatment Period 1), 8 weeks (Treatment Period 2) ]Validated scale consisting of 10 items with different weighting assessing severity of symptoms in MG. Results are reported as change from baseline to 8 weeks of treatment in both treatment periods (Visit 4 compared to Visit 2, and Visit 7 compared to Visit 5).
- Myasthenia Gravis Impairment Index [ Time Frame: 8 weeks (Treatment Period 1), 8 weeks (Treatment Period 2) ]22 patient-reported and 6 examination items. Results are reported as change from baseline to 8 weeks of treatment in both treatment periods (Visit 4 compared to Visit 2, and Visit 7 compared to Visit 5).
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Generalized myasthenia gravis (MGFA IIa-IVb) at screening, verified by ≥ 1 of the following: 1) AchR-antibodies in medical history, 2) Abnormal decrement on repetitive nerve stimulation in medical history
- Disease duration of ≥ 1 year
- Stable dose of antimyasthenic medications at screening
- Residual symptoms with a MG-QOL15 score of ≥ 10
- Age ≥ 18 years
- Ability to understand the requirements of the trial and provide written, informed consent
Exclusion Criteria:
- Evidence of malignancy ≤ 3 years prior to screening, unless deemed completely cured
- Thymectomy ≤ 6 months prior to screening
- Impending MG crisis or respiratory insufficiency
- Worsening of MG symptoms due to other diseases or medications (e.g. infection, beta-blockers, aminoglycosides, etc.)
- Other factor(s) or medical condition(s) that may explain residual symptoms
- Pregnancy or breast-feeding
- Treatment with beta-agonists
- Uncontrolled diabetes
- Ischemic Heart Disease, Cardiac Arrhythmia or Heart Failure (including hypertrophic cardiomyopathy)
- Uncontrolled Hypertension (≥ 160/110)
- Known hypersensitivity to any of the study drug components
- Treatment with tricyclic antidepressants, monoamineoxidase inhibitors, digoxine, or methylxanthines.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03914638
Contacts
| Contact: Jan LS Thomsen, MD | 78450000 ext 0045 | jathms@rm.dk |
Locations
| Denmark | |
| Department of Neurology, Aalborg University Hospital | Not yet recruiting |
| Aalborg, Denmark, 9000 | |
| Neurology, Aarhus University Hospital | Recruiting |
| Aarhus, Denmark, 8200 | |
Sponsors and Collaborators
University of Aarhus
Investigators
| Study Director: | Jan LS Thomsen, MD | Department of Clinical Medicine, Aarhus University |
| Responsible Party: | Jan Lykke Scheel Thomsen, MD, PhD Fellow, University of Aarhus |
| ClinicalTrials.gov Identifier: | NCT03914638 History of Changes |
| Other Study ID Numbers: |
BETA-MG-01 |
| First Posted: | April 15, 2019 Key Record Dates |
| Last Update Posted: | April 17, 2019 |
| Last Verified: | April 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Muscle Weakness Myasthenia Gravis Muscular Diseases Musculoskeletal Diseases Neuromuscular Manifestations Neurologic Manifestations Nervous System Diseases Pathologic Processes Signs and Symptoms Autoimmune Diseases of the Nervous System Neuromuscular Junction Diseases Neuromuscular Diseases Autoimmune Diseases Immune System Diseases Albuterol |
Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Asthmatic Agents Respiratory System Agents Tocolytic Agents Reproductive Control Agents Adrenergic beta-2 Receptor Agonists Adrenergic beta-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |